Insight · Medicines safety
Insight — high-risk drug monitoring — done properly.
Why monitoring slips.
Monitoring gaps almost never stem from clinical oversight. They stem from recall systems that depend on patients turning up, search lists that are not run consistently, and clinical capacity that is absorbed by acute work. The patients most likely to drop out of monitoring are the ones who feel well — exactly the patients whose blood result might be the first sign of toxicity, renal decline or marrow suppression. A structured monitoring programme replaces opportunistic recall with proactive search, technician-led contact and pharmacist sign-off.
The high-risk groups
Drug classes that need a structured monitoring programme.
- DMARDs — methotrexate, azathioprine, sulfasalazine, leflunomide, mycophenolate
- Lithium — levels, renal and thyroid function
- Amiodarone — thyroid, liver and pulmonary monitoring
- Anticoagulants — INR for warfarin, renal function for DOACs
- Antipsychotics — physical health monitoring including HbA1c and lipids
- Long-term opioids and gabapentinoids — review and de-prescribing audit
How the programme runs
Pharmacist plus technician, weekly cadence.
A working high-risk monitoring programme combines technician capacity with pharmacist clinical oversight. Technicians run the search lists, identify patients overdue for monitoring, contact them, book bloods and chase non-responders. The pharmacist reviews each result against the relevant monitoring framework, acts on out-of-range results, adjusts doses where indicated and within scope, and signs off the audit trail. Weekly cadence makes the difference — running the search list quarterly almost always lets gaps reopen between sweeps.
- Weekly search list run by technician
- Patient contact and blood booking by technician
- Pharmacist clinical review of results
- Dose adjustment within IP scope where appropriate
- Escalation to GP for out-of-scope changes
- Monthly audit summary to the practice and PCN
What good evidence looks like.
A high-risk drug monitoring programme should be defensible at audit. That means a documented monitoring schedule per drug group, search lists that have been run on a defined cadence, contact attempts that are evidenced for patients who did not attend, and a clear escalation route for out-of-range results. The audit trail protects the patient, the prescriber, the practice and the PCN — and it is the same evidence base that satisfies CQC, ICB and indemnity reviews if a safety event ever needs to be investigated.
Common audit findings
What inspectors flag most often.
- DMARD monitoring overdue with no documented patient contact
- Lithium levels overdue in patients on long-term therapy
- Anticoagulant renal monitoring missing in older patients
- Antipsychotic physical health monitoring incomplete
- No documented escalation when results were out of range
FAQs — high-risk drug monitoring.
Can technicians do this work?+
Yes. ARRS-funded technicians are well suited to the search, contact and pre-screening work that drives the programme, with pharmacist sign-off on clinical decisions.
How long does it take to close a backlog?+
Most practices close the majority of a monitoring backlog within 8 to 12 weeks with a dedicated technician day and pharmacist sign-off each week.
Does this satisfy QOF and IIF?+
Yes — monitoring directly contributes to medication safety indicators in both frameworks.
What if the patient won't engage?+
Documented contact attempts and a final clinical decision (continuation with caveats, dose pause, or referral) protect the prescriber and the patient.
Building the case to your ICB.
High-risk monitoring programmes are some of the easiest pieces of pharmacist and technician work to justify to an ICB Medicines Optimisation lead because the harm pathway is unambiguous and the evidence base is well established. NICE, BNF and the MHRA each publish monitoring frameworks for the drug groups concerned, and most ICBs already track audit data showing how often monitoring slips. A PCN that volunteers to run a structured monitoring programme — with monthly outcome reporting and a clear escalation pathway — is almost always seen as taking a piece of ICB-priority work off the shoulders of the wider system.
Where this matters operationally is in the conversation about ARRS allocation. ICBs increasingly want to see that PCN spend is producing measurable, evidence-backed change against system priorities, and a high-risk monitoring catch-up programme is one of the cleanest ways to demonstrate exactly that. The work pays back twice: once through the harm it prevents in the cohort, and a second time through the conditions it creates for future allocation conversations.
Talk to BCS.
If you'd like to walk through what this would look like for your PCN specifically, talk to our Service Development team. We'll cost a plan against your remaining ARRS allocation and your existing pharmacy workforce, and have a written proposal back within a week.
Talk to our Service Development team
30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.